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Abstract 
Persistence or recurrence of angina after a percutaneous coronary intervention (PCI) may affect about 
20-40% of patients during short-medium term follow-up. This appears to be true even when PCI is 
“optimised” using physiology-guided approaches and drug-eluting stents. Importantly, persistent or 
recurrent angina post-PCI is associated with a significant economic burden. Healthcare costs may be 
almost 2-fold higher among patients with persistent or recurrent angina post-PCI versus those who 
become symptom-free. However, practice guideline recommendations regarding the management of 
patients with angina post-PCI are unclear. Gaps in evidence into the mechanisms of post-PCI angina 
are relevant, and more research seems warranted. The purpose of this document is to review potential 
mechanisms for the persistence or recurrence of angina post-PCI, propose a practical diagnostic 
algorithm and summarize current knowledge gaps.  
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Introduction 
Procedural success is routinely achieved in patients with obstructive coronary artery disease 
(CAD) undergoing percutaneous coronary intervention (PCI). In the current European Society of 
Cardiology guidelines on stable obstructive CAD, coronary revascularisation has a Class 1, Level A 
recommendation on prognostic grounds for patients with left main stem disease or multivessel CAD, 
and also for symptoms in the presence of limiting angina or angina-equivalent, unresponsive to 
optimal medical therapy (1). Persistence or recurrence of angina after PCI is well recognised and may 
affect about 20-40% of patients during short-medium term follow-up (2-7). This appears to be true 
even when PCI is “optimised” using physiology-guided approaches [e.g. fractional-flow reserve 
(FFR) or non-hyperaemic pressure ratio (NHPR)] (8) and drug-eluting stents (DES) or stents with 
bioresorbable scaffolds (9). Importantly, persistent or recurrent angina post-PCI is associated with a 
significant economic burden. Healthcare costs may be almost 2-fold higher among patients with 
persistent or recurrent angina post-PCI versus those who become symptom-free (10). Furthermore, 
the role of PCI for symptom relief, when added to optimal medical therapy, remains a controversial 
issue (11-14). In the ORBITA trial, the benefits of PCI compared to a “sham control” placebo were 
unclear. One potential mechanism for persistent angina post-PCI identified by the investigators was 
microvascular angina (2), although this trial has been criticised because of methodological limitations 
(15).  
The clinical importance of angina recurrence following successful PCI is evident from 
developments in clinical quality registries, where post-PCI angina is being utilized as a clinical 
performance marker for PCI (16). Despite this, while prospective studies have documented that 
angina, including with inducible ischaemia, is a contributing factor in many patients with chest 
discomfort symptoms post-PCI (17), few studies have systematically addressed the mechanisms 
responsible for the recurrent angina (18,19) and there are no comprehensive recommendations for its 
diagnosis or treatment (1,20). 
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The purpose of this document, which expands and gives a global perspective to what we have 
previously published (3), is to review potential mechanisms for the persistence or recurrence of 
angina post-PCI, propose a practical diagnostic algorithm, and summarize current knowledge gaps.  
 
Mechanisms of persistent or recurrent angina after PCI 
Elective PCI in patients with stable angina is routinely successful and procedure-related 
problems are uncommon. Procedural success reflects effective education and training, the 
availability of state-of-the-art stent technologies, use of adjunctive intravascular imaging and 
physiology techniques, and quality assurance (21).  
Despite procedural success, angina may persist or recur in a large proportion of patients, 
which is frustrating for patients and clinicians. In contemporary practice, clinicians are focused on 
identifying a “flow-limiting” stenosis amenable to PCI with stents when sometimes other potential 
causes are relevant. This issue could be considered as ‘detection bias’.  
Yet, the pathophysiology of persisting or recurring angina after successful PCI is 
heterogeneous. Aside from non-cardiac causes of angina, structural and functional alterations in the 
coronary circulation may be implicated (Table 1 and Figure 1).  
 
Flow limiting epicardial obstructions  
Stent thrombosis and in-stent restenosis are infrequent causes of recurrent angina and 
ischaemia after PCI in contemporary clinical practice with rates of stent thrombosis <1% at 1-year 
and 0.2-0.4% per year thereafter, and rates of clinically relevant in-stent restenosis of 5% at 1-year 
follow-up (22). Recurrence rate of major adverse cardiac events due native vessel disease progression 
is < 5% at 1-year follow up (23), although disease progression and cardiac events are higher in 
patients with diabetes (24).  
Persistence of angina caused by incomplete coronary may occur in up to 30% in the current 
era, although definitions of incomplete revascularisation are heterogeneous (25).  
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Other potential causes of angina post-PCI include diffuse atherosclerosis without a focal 
stenosis leading in turn to an insidious pressure gradient along the length of the coronary artery, 
coronary dissection, myocardial bridging and thromboembolism, all of which may have been 
overlooked during the index procedure.  
 
Coronary vasomotion disorders of epicardial arteries and microcirculation 
Functional causes of persistent or recurrent angina following a technically successful PCI 
include vasomotion disorders of epicardial coronary arteries, as well as coronary microvascular 
dysfunction (CMD). Accordingly, current European Society of Cardiology guidelines on stable CAD 
have acknowledged the role of coronary vascular dysfunction in causing angina post-PCI (1). If 
vasomotor function has not been specifically assessed in a patient with angina before undergoing PCI, 
it is impossible to know the time-course of these functional alterations. Of note, stent implantation 
may cause or enhance coronary vascular dysfunction increasing the propensity of epicardial coronary 
vasospasm and/or CMD. Overall, these functional mechanisms may be causally implicated in about 
half of patients with angina post-PCI although, again, prospective studies are lacking (3).  
Significant constriction of epicardial coronary arteries at or distal to the PCI site is a potential 
cause of recurrent angina (26). Ong et al. (27) documented epicardial spasm (>75% narrowing), 
associated with reproduction of patient’s symptoms, in response to intracoronary acetylcholine (ACh) 
at increasing doses; up to 200 µg for the left coronary artery or with 80 µg for the right coronary 
artery (Figure 2). Significant constriction occurred in about half of the patients undergoing coronary 
angiography for post-PCI recurrent angina without haemodynamically significant coronary stenoses. 
These observations support a mechanistic role for epicardial coronary artery constriction in patients 
with angina persistence or recurrence post-PCI. Heightened activation of the Rho-kinase pathway, a 
central molecular mechanism for vascular smooth muscle constriction, might also be involved in the 
pathogenesis of DES-related enhanced epicardial artery constriction (28).   
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CMD in post-PCI angina, type-3 by the classification of Camici and Crea (29), can be caused 
by impaired microvascular dilation resulting in a reduction of coronary flow reserve, similar to that 
caused by an epicardial stenosis, or by microvascular spasm (Figure 2). In a study of patients with 
post-PCI recurrent angina compared to matched patients without angina post-PCI, Li et al. (30) 
observed a more profound reduction in coronary blood flow (CBF) in association with an increase in 
the index of microvascular resistance (IMR) in response to intravenous adenosine (140 µg/kg/min). 
The impairment of hyperaemic CBF and increase in IMR was even more relevant in those with 
abnormal exercise stress test (EST) result and persisted at 6- and 12-month follow-up. These findings 
are consistent with studies using transthoracic Doppler echocardiography by Milo et al. (31). In their 
study, hyperaemic coronary artery blood flow velocity in the left anterior descending (LAD) was 
impaired at 1-day, 3- and 6-months after successful PCI compared to controls. Importantly, similar 
impairment of the CBF response to cold pressor testing was also observed, suggesting impaired 
endothelium-dependent vasodilator function of the coronary microcirculation. Furthermore, a greater 
impairment of the CBF response predicted restenosis in the LAD coronary artery during long-term 
follow-up (32). Among patients who underwent PCI with second-generation DES, Hokimoto et al. 
(33) found impaired CBF response to both ACh (an endothelium-dependent stimulus) and adenosine 
(mostly an endothelium-independent stimulus). Overall, in this study, evidence of CMD was evident 
in 59% of patients with previous PCI. Finally, Ong et al. suggested coronary microvascular spasm 
might contribute to post-PCI recurrent angina in approximately 1 in 5 affected patients (27). 
Specifically, following intra-coronary infusion of acetylcholine, affected patients experienced angina 
and ischaemic ECG changes without evident epicardial constriction, suggesting microvascular spasm 
rather than epicardial constriction was causal for the angina.  
Mechanisms underlying CMD post-PCI are poorly understood, heterogeneous, and potentially 
more than one problem may be operative in any given patient (34). First, chronic coronary 
microcirculation adaptation to reduced perfusion pressure distal to a stenosis or to an occlusion would 
be expected to negatively influence microvascular remodelling and its capacity to maximally dilate 
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 7 
after restoration of a more physiologic perfusion pressure. Furthermore, the time required for the 
coronary microcirculation to recover to baseline vasomotor reactivity is likely to be variable between 
patients (35).  
Second, PCI might contribute to CMD by causing microembolisation of debris material, 
which may obstruct small coronary arteries, arterioles and/or capillaries to cause perivascular 
inflammation and even capillary obliteration and cardiomyocyte injury (36). Furthermore, the DES 
per se causes vasoconstriction in the adjacent and downstream coronary macro- and microcirculation, 
potentially due to elution of the active drug and polymer constituents downstream. Although these 
detrimental effects of DES might be mediated by endothelial dysfunction (37), more recent studies 
suggest that they are mainly mediated by activation of Rho-kinase in smooth muscle cells and, 
accordingly, are prevented by Rho-kinase inhibitors (38,39).   
Third, CMD may have pre-dated the index PCI procedure which was “unmasked” when the 
epicardial obstruction was relieved by PCI.  In particular, CMD with microvascular rarefaction is 
implicated in heart failure with preserved ejection fraction (40,41).  
Last but not least, coronary microcirculation regulates myocardial blood flow, and therefore 
shear stress in large epicardial arteries which in turn directs vessel remodelling and plaque formation.   
 
Diagnostic evaluation of persistent or recurrent angina after PCI 
Non-invasive diagnostic tests 
European Society of Cardiology guidelines for stable obstructive CAD recommend a stress 
test at follow-up in patients with persistent or recurrent angina post-PCI, preferably a stress test that 
is combined with imaging (Class I, level of evidence C) (1). Thus, non-invasive stress tests represent, 
in most cases, the first diagnostic assessment for patients presenting with angina post-PCI. 
ECG stress testing in the diagnostic and prognostic assessment of patients with stable 
ischaemic heart disease is well established as it helps guide the initial treatment strategy (1).The 
diagnostic performance of CTCA for the evaluation of in-stent restenosis is generally lower than in a 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 8 
native vessel, and adjunctive estimation of fractional flow reserve (FFR-CT) in a vessel with a stent 
is relatively contra-indicated (42). The role of ECG stress testing alone after PCI is debated because 
the positive predictive value for obstructive stenosis/restenosis is only moderately high (43). A key 
issue is that an abnormal ECG stress test can be caused by both obstructive CAD and functional 
mechanisms (CMD, epicardial vasoconstriction, etc.). In both clinical scenarios, evidence of 
exertional angina and ECG abnormalities consistent with ischaemia provide objective evidence that 
should be useful for onward management.  
Similar considerations apply to stress myocardial perfusion imaging by single photon 
emission tomography (SPECT). Positron emission tomography (PET) is a well-validated technique 
that provides non-invasive, accurate, and reproducible quantification of both global and regional 
myocardial blood flow (MBF; ml/g/min) and coronary flow reserve (CFR). Clinical research using 
PET has provided substantial new knowledge on CMD in various clinical settings. Indeed, evidence 
of segmental abnormalities more often implicates an epicardial problem while CMD is associated 
with a global reduction of CFR (44,45). Recent studies suggest that cardiac magnetic resonance may 
discriminate between epicardial and microvascular causes of myocardial ischaemia (46,47). 
Stress echocardiography (with either exercise or pharmacological stressor) may be useful to 
distinguish between epicardial and microvascular coronary mechanisms. Indeed, a dissociation 
between angina and ischemic ST segment changes on the one hand and lack of regional wall motion 
abnormalities on the other hand, is a typical feature of microvascular angina due to the patchy 
distribution of ischemia in this setting (48-51). In sharp contrast, as established in the ischemic 
cascade concept where regional wall motion abnormalities precede electrical abnormalities 
and both precede symptoms,  it is very unlikely for patients with epicardial coronary stenoses 
to experience angina and ischemic ST segment changes in the absence of regional wall motion 
abnormalities (48).  
 
Invasive diagnostic tests 
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Current European Society of Cardiology guidelines on stable CAD recommend invasive 
coronary angiography in clinically stable patients with high-risk ischaemic findings (>10% of 
myocardium) at stress imaging (Class I, level of evidence C) (1). However, the threshold for coronary 
angiography might be lower after high risk PCI (Class IIb, level of evidence C) (1). Considering the 
limited negative predictive value of a non-invasive test, then an invasive approach may be chosen 
independent of non-invasive test results, particularly when the history is strongly supporting angina 
recurrence because it offers the opportunity to test both structural and functional alterations of 
coronary circulation (Figure 3). Multi-territory ischaemia (both transmural and regional) may not be 
detected by non-invasive tests (3). Moreover, patients with persistent or recurrent angina and 
incomplete revascularisation need to be reassessed if additional revascularisation is considered to be 
technically feasible. Finally, in case of an intermediate stenosis on coronary angiography, FFR or 
NHPR measurements can be helpful to confirm the presence of a haemodynamically significant 
epicardial stenosis. However, the caveat is that in the presence of CMD, it may be unclear whether 
near maximal hyperaemia is achieved, thus limiting the usefulness of FFR measurements without 
measuring CFR or indices of myocardial resistance (52).   
A second indication for coronary angiography is the occurrence of angina at rest, despite 
optimal medical treatment and negative non-invasive testing. This scenario should strongly suggest 
functional coronary alterations. In this patient subset, invasive coronary angiography might 
sometimes establish the presence of subcritical unstable coronary plaques, which can be further 
investigated by intravascular imaging (OCT, IVUS, etc.). In the absence of subcritical unstable 
plaques, the assessment of epicardial and microvascular coronary vasomotion may reveal functional 
causes of persistent angina. In both scenarios, invasive coronary angiography is necessary to elucidate 
the causes of angina. 
Coronary artery vasomotion is mainly assessed invasively, usually by intracoronary 
administration of drugs, such as ACh or ergonovine (1,3). The safety of intracoronary provocative 
testing has been convincingly proven in previous studies (53). Some have advocated non-invasive 
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assessments using ergonovine stress echocardiography in patients known to have non-obstructive 
CAD (54). Coronary vasomotion in response to acetylcholine reflects the interplay between 
endothelial and smooth muscle cell responses. Acetylcholine elicits endothelium-dependent 
vasodilatation when the endothelium is functional, but in pathological conditions, characterised by 
endothelial dysfunction and/or smooth muscle cell hyperreactivity, it may result in no dilatation or 
even trigger vasoconstriction or spasm via stimulation of smooth muscle cell muscarinic receptors. 
Ergonovine acts primarily via serotoninergic receptors on vascular smooth muscle cells but also on 
α-adrenergic and dopaminergic receptors, unmasking predisposition to vasoconstriction or spasm. 
ACh is preferred because it is relatively short-acting, specific in its selectivity for muscarinic 
receptors and the intracoronary dosing is devoid of systemic effect; whereas ergonovine effects 
multiple receptors, is longer acting and even with intracoronary dosing may have some systemic 
effects (blood pressure increases). Nevertheless, at present, it is unclear whether ACh or ergonovine 
is superior to detect spasm in patients with persisting angina post-PCI also because they might 
identify different subsets of patients with vasospastic angina (55). 
Coronary artery spasm is defined as a transient (e.g. reversible) coronary artery occlusion/sub 
occlusion (> 90% narrowing) with signs (ST changes) and symptoms of myocardial ischaemia 
(56,57). Spasm may involve discrete coronary segments in one or multiple arteries, or can be diffuse 
and, when it involves distal coronary vessels, can be suspected to also extend into the 
microvasculature (56).  
Lack of epicardial coronary spasm by angiography in the presence of ischaemic ECG changes 
and angina suggests microvascular spasm (58). When epicardial spasm occurs, objective 
determination of concomitant microvascular spasm is difficult.    
Coronary reactivity testing is only performed in a limited number of cardiac catheterization 
laboratories worldwide. The reasons for the low adoption of coronary reactivity testing are 
multifactorial and include lack of evidence from randomised controlled trials, and lack of education 
and training in who to administer the tests. The European Society of Cardiology (ESC) and the 
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American College of Cardiology (ACC)/American Heart Association (AHA) guidelines make spasm 
provocation testing only Class IIa and Class IIb, respectively (1,20).  However, the Japanese 
Circulation Society and the Coronary Vasomotion Disorders International Study Group (COVADIS) 
have recommended routine testing in selected patients (56-58).  
CFR and microvascular resistance can be measured using a pressure- and flow-sensitive 
Doppler catheter or a thermodilution guidewire. These techniques can be performed during coronary 
angiography enabling a comprehensive assessment of CMD by assessing microvascular dilatory 
function (59,60), which may complement coronary reactivity testing within the same procedure.  
The Coronary Microvascular Angina clinical trial (CorMicA) is the first to prove the 
diagnostic, health and economic value of an interventional diagnostic procedure, which combines a 
guidewire and coronary vasoreactivity testing, to inform the diagnosis and treatment of patients with 
angina and no obstructive CAD, where the primary outcome is Seattle Angina Score at 6 months (61).   
 
Diagnostic flow chart 
 We recognise that randomised controlled trials for management of post-PCI angina are 
lacking. Nonetheless, given the clinical necessity, practice guidelines are needed. Although symptom 
assessment is important, it is frequently insufficient to establish the cause of persistent or recurrent 
angina after PCI, the only distinctive feature of vasospastic angina being angina at rest, frequently 
nocturnal, with preserved effort tolerance (62) and the only distinctive feature of microvascular 
angina being prolonged chest pain not immediately responsive to nitrates (63). We propose a 
diagnostic algorithm that may assist in the evaluation of patients in this setting (Figure 4). The 
rationale prioritises a person-centred approach with diagnostic tests according to local availability 
and onward management, including coronary angiography, as appropriate. A non-invasive 
assessment will be sufficient in some patients, but in many cases, invasive management including to 
assess coronary vascular function will be needed.  
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Knowledge gaps 
Patients with persistent or recurrent angina post-PCI present an unmet clinical need. Recent 
studies suggest that PCI may not be relied upon to improve angina (2). The large International Study 
of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) clinical 
trial is assessing the benefits of revascularisation in addition to OMT to improve health outcomes 
(64). A recent study demonstrated that a simple non-invasive assessment of peripheral artery 
endothelial function during index PCI admission predicted the persistence or recurrence of 
angina/ischaemia at follow-up (65), suggesting that assessment of endothelial dysfunction (66) may 
be useful for prediction of structural treatment benefit. We recognise that such tests are not feasible 
in daily practice, but the implication is that treatments which improve endothelial dysfunction may 
be beneficial. This possibility merits further prospective research.  
 In clinical practice, PCI for stable angina patients is currently a “one-size-fits-all” approach, 
potentially useful for symptom relief in some symptomatic patients found to have epicardial 
obstructive CAD. In other patients, a significant epicardial stenosis may reflect more extensive 
vascular dysfunction, where PCI alone may be ineffective. We think more research is warranted into 
the prevalence and clinical significance of coronary vascular dysfunction in patients undergoing PCI.  
When obstructive CAD is ruled out, post-PCI angina may be due to coronary vascular dysfunction 
caused by either increased IMR, epicardial or microvascular spasm, or both. In these circumstances, 
repeat PCI would be unlikely to be beneficial. An important knowledge gap is treatment of CMD 
(67). Importantly, early evidence suggests that an empirical treatment of angina in the absence of 
obstructive coronary atherosclerosis guided by the assessment of functional coronary alterations is 
associated to a better outcome as compared to a strategy guided by angiography only (61). 
Finally, while current guidelines on percutaneous coronary revascularization do not fully address 
the issue of persistent/recurrent angina, it would be desirable to do so in the future (68). 
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Legends to figures 
 
Figure 1 
Structural and functional alterations of coronary circulation responsible for persistence or 
recurrence of angina after percutaneous coornary intervention. 
 
 
Figure 2 
Top panels: Epicardial coronary spasm: representative images of a 55 year old male patient with 
several previous stent implantations in the right coronary artery (RCA) (red lines). The patient 
reported recurrent resting angina and underwent invasive coronary angiography. The RCA showed 
mild in-stent-proliferation. Intracoronary acetylcholine (A-Ch) testing revealed spasm of the RCA 
distal to the stents at 80µg with reproduction of the reported symptoms (A). After intracoronary 
nitroglycerine injection (400µg) the spasm and the symptoms resolved (B). 
Bottom panels: Coronary microvascular spasm: representative images of a 64 year old female patient 
with previous stent implantation in the left anterior descending artery (LAD) (red lines). The patient 
reported recurrent angina at rest as well as during exertion and underwent invasive coronary 
angiography. The LAD showed mild in-stent-proliferation. Intracoronary acetylcholine testing 
revealed no epicardial spasm at 200 µg, but reproduction of the reported symptoms together with 
ischemic ECG shifts on the simultaneously recorded 12-lead ECG (C). After intracoronary 
nitroglycerine injection (200 µg) the ischemic ECG changes and the symptoms resolved (D). 
 
Figure 3 
A full investigation of the mechanisms of persistence or recurrence of angina after percutaneous 
coronary intervention in the catheterization laboratory should include the assessment of both 
structural and functional alterations of epicardial coronary arteries and of coronary microcirculation. 
A-Ch = acetyl-choline; CFR= coronary flow reserve; IVUS = intravascular ultrasounds; OCT = 
optical coherence tomography. 
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Figure 4 
 
Diagnostic flow chart in patients with persistent or recurrent angina after PCI. Colour coding: 
symptoms in yellow, diagnostic tools in purple, diagnostic findings in green and therapeutic 
recommendations in red. 
A-Ch = acetylcholine, CFR = coronary flow reserve; Ergo = ergonovine maleate; FFR = fractional 
flow reserve; NHPR = non-hyperaemic pressure ratio; IMR = index of microvascular resistance; 
RWMA = regional wall motion abnormalities.  
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Table 1. Cause of persistence or recurrence of angina post-PCI 
Mechanisms Diagnostic criteria 
Flow limiting epicardial obstructions  
Stent failure  
In-stent restenosis Presence of ≥70% stenosis in the stented segment and within 5 
mm of stent edges at coronary angiography. Intermediate 
lesions should be interrogated with FFR. 
Stent thrombosis (definite) Presence of intracoronary thrombus that originates in the stent 
or segment 5 mm proximal or distal to the stent and presence of 
at least 1 of the following within a 48-hour time window: 
 Acute onset of ischaemic symptoms at rest 
 New ischaemic ECG changes that suggest acute ischemia 
 Typical rise and fall in cardiac biomarkers 
 
CAD progression Progression of coronary atherosclerosis in coronary segments 
different from those treated with index PCI, with presence of 
≥70% stenosis at coronary angiography. Intermediate lesions 
(40-70% diameter stenosis) should be interrogated with FFR. 
Incomplete revascularisation Residual stenosis of ≥50% in the left main coronary artery 
or ≥70% in another major epicardial coronary artery after index 
PCI. Intermediate lesions (40-70% stenosis) should be 
interrogated with FFR. 
Diffuse coronary atherosclerosis Diffuse coronary atherosclerosis at coronary angiography 
without angiographically significant stenosis, determining 
myocardial ischaemia as documented by reduced FFR (≤0.80). 
Myocardial bridge Disclosure at coronary angiography of a systolic narrowing, or 
“milking” of the vessel, with a “step-down” and “step-up” 
demarcating the affected area, and complete or partial 
decompression in diastole. Diastolic FFR with dobutamine 
challenge is a more appropriate approach for testing the 
haemodynamic significance of myocardial bridges. 
Spontaneous coronary artery 
dissection (SCAD) 
SCAD is defined as a separation within the arterial wall by 
intramural hematoma, which can occur by an intimal rupture 
initiating medial dissection or more commonly by a 
spontaneous intramedial haemorrhage resulting from disruption 
of the vasa vasorum  
  
Coronary vasomotion disorders of 
epicardial arteries and 
microcirculation 
 
Epicardial spasm Presence of focal or diffuse epicardial coronary diameter 
reduction ≥ 90% during intracoronary ACh or ergonovine 
administration in comparison with the relaxed state following 
intracoronary nitroglycerin given to relieve the spasm, 
associated with reproduction of symptoms and ischaemic ECG 
shifts. 
Microvascular spasm Typical ischaemic ST-segment changes and angina developed 
during intracoronary ACh or ergonovine administration in the 
absence of epicardial coronary constriction ≥90% diameter 
reduction. 
Impaired coronary microvascular 
dilation 
Reduction of coronary flow reserve (CFR<2.0-2.5) in the 
absence of obstructive epicardial stenoses. Increase in the index 
of microvascular resistance (>25) or the hyperaemic myocardial 
resistance (HMR ≥2 mmHg/cm/s) 
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Abstract 
Persistence or recurrence of angina after a percutaneous coronary intervention (PCI) may affect up to 
20-40% of patients at 1-year follow up. This appears to be true even when PCI is “optimised” using 
physiology-guided approaches and drug-eluting stents. Importantly, persistent or recurrent angina 
post-PCI is associated with a significant economic burden. Healthcare costs may be almost 2-fold 
higher among patients with persistent or recurrent angina post-PCI versus those who become 
symptom-free. However, practice guideline recommendations regarding the management of patients 
with angina post-PCI are unclear. Gaps in evidence into the mechanisms of post-PCI angina are 
relevant, and more research seems warranted. The purpose of this document is to review potential 
mechanisms for the persistence or recurrence of angina post-PCI, propose a practical diagnostic 
algorithm and summarize current knowledge gaps.  
 
Abstract
  
ICMJE Conflicts of Interest form (1 for each author listed)
Click here to access/download
ICMJE Conflicts of Interest form (1 for each author
listed)
COI Bairey.pdf
  
ICMJE Conflicts of Interest form (1 for each author listed)
Click here to access/download
ICMJE Conflicts of Interest form (1 for each author
listed)
COI Beltrame.pdf
  
ICMJE Conflicts of Interest form (1 for each author listed)
Click here to access/download
ICMJE Conflicts of Interest form (1 for each author
listed)
COI Berry.pdf
  
ICMJE Conflicts of Interest form (1 for each author listed)
Click here to access/download
ICMJE Conflicts of Interest form (1 for each author
listed)
COI Camici.pdf
  
ICMJE Conflicts of Interest form (1 for each author listed)
Click here to access/download
ICMJE Conflicts of Interest form (1 for each author
listed)
COI Crea.pdf
  
ICMJE Conflicts of Interest form (1 for each author listed)
Click here to access/download
ICMJE Conflicts of Interest form (1 for each author
listed)
COI Kaski.pdf
  
ICMJE Conflicts of Interest form (1 for each author listed)
Click here to access/download
ICMJE Conflicts of Interest form (1 for each author
listed)
COI Ong.pdf
  
ICMJE Conflicts of Interest form (1 for each author listed)
Click here to access/download
ICMJE Conflicts of Interest form (1 for each author
listed)
COI Pepine.pdf
  
ICMJE Conflicts of Interest form (1 for each author listed)
Click here to access/download
ICMJE Conflicts of Interest form (1 for each author
listed)
COI Sechtem.pdf
  
ICMJE Conflicts of Interest form (1 for each author listed)
Click here to access/download
ICMJE Conflicts of Interest form (1 for each author
listed)
COI Shimokawa.pdf
